Furthermore, using the currently defined cell surface markers of breast cancer stem cells (CD44+/24-) we have identified enrichment of stem cell-like activity and migration within low proliferative cells, and showed differential effects of stem cell signalling inhibitors (DKK1 and DBZ) within subgroups of stem-like cells dependant upon their proliferative status. The gene discussed is CD44; the disease is breast carcinoma.